statin

Overview

Statins (formally classified as 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, or HMG-CoA reductase inhibitors) are a class of lipid-lowering agents that competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for endogenous cholesterol biosynthesis. By blocking this enzymatic step, statins reduce hepatic cholesterol production and upregulate low-density lipoprotein (LDL) receptor expression on hepatocytes, thereby lowering circulating LDL cholesterol and reducing the risk of atherosclerotic cardiovascular disease. First approved for clinical use in the late 1980s, statins have become among the most widely prescribed drugs globally and are considered a cornerstone of primary and secondary cardiovascular prevention. Common members of this drug class include Atorvastatin and simvastatin, which differ in their lipophilicity, potency, and metabolic profiles — properties that influence both their efficacy and their safety signatures across organ systems.

Beyond their canonical cholesterol-lowering mechanism, statins exhibit a range of pleiotropic effects — including anti-inflammatory, immunomodulatory, and antioxidant activities — that are only partially explained by reductions in LDL cholesterol or modulation of the mevalonate pathway. These additional biological actions have positioned statins as candidate therapies or adjuncts in a growing number of disease contexts beyond cardiovascular disease, including oncology, liver disease, neurological conditions, and inflammatory disorders. Their broad biological footprint, however, also underlies a spectrum of adverse effects and drug interactions that continue to be characterized in large-scale clinical and genetic studies.

Recent Publications Focus

Below is a summary of the newest research publications targeting statin (sorted by publication date).

Recent studies have continued to examine statins in acute and preventive cardiovascular settings, including combination strategies and real-world effectiveness. A randomized trial is evaluating whether immediate intensive statin therapy adds benefit when combined with clopidogrel-aspirin in patients with mild ischemic stroke or transient ischemic attack. Another randomized controlled trial is assessing statin plus dapagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, in ischemic heart disease with heart failure, focusing on potential synergistic effects on ejection fraction and laboratory measures. In parallel, a target trial emulation study is examining the cardiovascular outcomes and safety of statin therapy for primary prevention in adults aged 75 years or older with type 2 diabetes, a population underrepresented in randomized trials.

Other publications have focused on statin adherence, safety, and patient-centered use. A multicentre randomized controlled trial protocol (AdLip) is testing a health coach-supported mobile health intervention designed to improve adherence to statins in adults with hyperlipidaemia. In older adults, an international vignette study found that willingness to deprescribe simvastatin was shaped by prior statin experiences, beliefs, and decision-making preferences, underscoring the importance of shared decision-making in deprescribing conversations. Genetic and pharmacologic variability in statin response is also being explored through a study of apolipoprotein E and SLCO1B1 polymorphisms and their impact on statin efficacy and safety in dyslipidemic patients.

Several recent observational and mechanistic studies have examined broader associations of statin use with noncardiovascular outcomes. In a national retrospective cohort study of metabolic dysfunction-associated steatotic liver disease, long-term statin use was associated with reduced hepatocellular carcinoma risk, and among patients with MASLD, use for more than 180 days was associated with lower risk than statin non-use in people without steatotic liver disease. A secondary analysis of the SPARTAN trial is evaluating statin use and survival outcomes in advanced prostate cancer. Another study found no significant association between statin use and diabetic peripheral neuropathy in NHANES data, although Mendelian randomization analyses suggested that genetically proxied inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase and PCSK9 may be associated with increased odds of diabetic peripheral neuropathy, and HMGCR and NPC1L1 inhibition may be associated with trigeminal neuralgia.

Additional work has placed statins in the context of atherosclerosis biology and residual risk assessment. A review of mitochondrial dysfunction in atherosclerosis noted that conventional therapies such as statins may partially mitigate symptoms but do not directly correct mitochondrial abnormalities, while highlighting mitochondrion-targeted delivery systems as a developing therapeutic strategy. In lipid risk prediction, a new metric called risk-weighted apoB was reported to outperform traditional lipid biomarkers and was described as a potentially better index of residual risk in statin-treated subjects. Finally, a triple-blinded randomized clinical trial is testing simvastatin for prevention of recurrent pancreatitis, reflecting ongoing interest in the anti-inflammatory properties of statins beyond lipid lowering.

Background PMIDs

• [PMID 41423587]
• [PMID 41655587]
• [PMID 41916005]
• [PMID 42044984]
• [PMID 42216396]

Method PMIDs

• [PMID 41372774]
• [PMID 41378867]
• [PMID 42414099]

Result PMIDs

• [PMID 42127206]

Target PMIDs

• [PMID 41482454]
• [PMID 41531191]
• [PMID 41568673]
• [PMID 41652814]
• [PMID 41654482]
• [PMID 41668545]
• [PMID 41861156]
• [PMID 42081017]
• [PMID 42085423]
• [PMID 42133048]
• [PMID 42340940]
• [PMID 42348803]